Riskpilot← Back to searchSign inGet full accessVimian Pharma Holding AB
ABActiveOrg 5591336093Economic activity was not specified by tax authority · NACE 0000Est. 20170 employees
Revenue 2024
SEK 0
EBITDA margin
—
+152% vs 2023
Equity ratio
100.0%
Financial strength
Net profit 2024
SEK 1,2M
+437% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK 22K | +152% |
| Net profit | SEK 1,2M | +437% |
| Total assets | SEK 1,8B | +0% |
| Equity | SEK 1,8B | +0% |
| Employees | 0 | — |
Legal name
Vimian Pharma Holding AB
Org number
5591336093
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
13 november 2017
Share capital
SEK 55 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Bolaget har till föremål för sin verksamhet att, direkt eller indirekt, äga och förvalta aktier och andelar i dotterbolag och intressebolag verksamma inom bland annat djurhälsovård och idka därmed förenlig verksamhet.
Address
Email
gabriel.fitzgerald@fideliocapital.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — |
| EBITDA | −29 | −13 | −28 | −907 | −4 | −42 | 22 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | — |
| EBIT | −29 | −13 | −28 | −907 | −4 | −42 | 22 |
| Net financials | — | — | 137 018 | 5 722 | 162 | 256 | 310 |
| Profit before tax | −29 | −13 | 136 990 | 4 815 | 158 | 214 | 1 161 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −11 |
| Net profit | −29 | −13 | 136 990 | 4 815 | 158 | 214 | 1 150 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 100 049 | 120 885 | 971 951 | 1 754 634 | 1 754 768 | 1 755 035 | 1 756 143 |
| Equity | 100 021 | 120 859 | 971 951 | 1 754 610 | 1 754 768 | 1 754 982 | 1 756 132 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Short-term debt | 28 | 26 | 0 | 24 | 0 | 54 | 11 |
| Total debt | 28 | 26 | — | 24 | — | 54 | 11 |
EBITDA margin
2200000.0%
This company
15.8%
Market median
+13923951% vs market
20182024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20182024
Return on equity
0.1%
This company
18.4%
Market median
-99% vs market
20182024
Net profit margin
115000000.0%
This company
8.1%
Market median
+1419752986% vs market
20182024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20182024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-11-01 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EC Audit | Audit | 2026 | — | — |
CR Audit | Audit | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2026 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2023 | — | — | |
| Chairman | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Vimian FinCo AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Fidelio Vet Holding AB
Vimian Pharma Holding AB Board members of Vimian Pharma Holding AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eva Camilla Nilsson | Audit | 0 companies |
| Carl-Johan Regell | Audit | 0 companies |
| Alireza Tajbakhsh | Chairman | 0 companies |
| Carl Gabriel Lindsay Fitzgerald | Board of Directors | 0 companies |
| Carl Fredrik Michael Ullman | Chairman | 0 companies |
| Theodor Simon Josef Bonnier | Board of Directors | 0 companies |
| Carl-Johan T Zetterberg Boudrie | Board of Directors | 0 companies |
| Erik Gunnar Öhlén | Board of Directors | 0 companies |
| Sven Johan Magnus Göte Kjellberg | Chairman | 0 companies |
| Martin Nilsson Erleman | Chairman | 0 companies |